• 提示：詳情請下載說明書。

• 產(chǎn)品描述： SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations

• 靶點(diǎn)： ERK2：1 nM (IC50)；ERK1：4 nM (IC50);ERK;?MEK

• 體內(nèi)研究：
  SCH772984 (12.5-50 mg/kg; i.p.; twice daily for 14 days) leads to 98% tumor regression. Dose-dependent antitumor activity is also observed in the KRAS-mutant pancreatic MiaPaCa model, with 36% regression at 50 mg/kg twice daily. Importantly, tumor regression is accompanied by robust inhibition of ERK phosphorylation in tumor tissue. SCH772984 is well tolerated on this schedule as measured by morbidity, lethality, or body weight loss。

• 參考文獻(xiàn)：
  1. Morris EJ, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013 Jul;3(7):742-50.

• 溶解性： DMSO  :  48  mg/mL  (81.68  mM;  Need  ultrasonic)

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	1.702 ml	8.508 ml	17.016 ml
  5 mM	0.34 ml	1.702 ml	3.403 ml
  10 mM	0.17 ml	0.851 ml	1.702 ml
  50 mM	0.034 ml	0.17 ml	0.34 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

• 1. [IF=12.4] Yuting Lin et al."Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization."Theranostics.2024; 14(2): 662–680

輸入產(chǎn)品批號：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *